People with color blindness may be less able to spot an early sign of bladder cancer, making them likelier to be diagnosed ...

D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory ...

A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.

No significant difference seen between patients with colorectal cancer and color vision deficiency versus those without color vision deficiency.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...

In a significant development for the field of oncology, ImmunityBio, Inc. (NASDAQ: IBRX) has recently announced positive results from its clinical trials focused on treating bladder cancer. This ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.

People who are colorblind may be missing a life-saving warning sign of bladder cancer. Analysis of the electronic health ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...